Pathology & Laboratory Medicine

Publications

Filter By Faculty

Filter by Principal Investigator

2020

Hsu JM, Chen Z, Shore T, Gergis U, Mayer S, Phillips A, et al. Outcomes of Allogeneic Stem Cell Transplant for Elderly Patients with Hematologic Malignancies. Biol Blood Marrow Transplant. 2020;26(4):789-797.

Nellis ME, Saini A, Spinella PC, Davis PJ, Steiner ME, Tucci M, et al. Pediatric Plasma and Platelet Transfusions on Extracorporeal Membrane Oxygenation: A Subgroup Analysis of Two Large International Point-Prevalence Studies and the Role of Local Guidelines. Pediatr Crit Care Med. 2020;21(3):267-275.

Au CM, Furness JB, Britt K, Oshchepkova S, Ladumor H, Soo KY, et al. Three-dimensional growth of breast cancer cells potentiates the anti-tumor effects of unacylated ghrelin and AZP-531. Elife. 2020;9.

Pea A, Yu J, Marchionni L, Noe M, Luchini C, Pulvirenti A, et al. Genetic Analysis of Small Well-differentiated Pancreatic Neuroendocrine Tumors Identifies Subgroups With Differing Risks of Liver Metastases. Ann Surg. 2020;271(3):566-573.

Westblade LF, Brar G, Pinheiro LC, Paidoussis D, Rajan M, Martin P, et al. SARS-CoV-2 Viral Load Predicts Mortality in Patients with and without Cancer Who Are Hospitalized with COVID-19. Cancer Cell. 2020;38(5):661-671.e2.

Laurence J, J Mulvey J, Seshadri M, Racanelli A, Harp J, Schenck EJ, et al. Anti-complement C5 therapy with eculizumab in three cases of critical COVID-19. Clin Immunol. 2020;219:108555.

Prabhu M, Cagino K, Matthews KC, Friedlander RL, Glynn SM, Kubiak JM, et al. Pregnancy and postpartum outcomes in a universally tested population for SARS-CoV-2 in New York City: a prospective cohort study. BJOG. 2020;127(12):1548-1556.

Day W, Gabriel C, Kelly RE, Magro CM, Williams JV, Werner A, et al. Juvenile dermatomyositis resembling late-stage Degos disease with gastrointestinal perforations successfully treated with combination of cyclophosphamide and rituximab: case-based review. Rheumatol Int. 2020;40(11):1883-1890.

Kadin ME, Adams WP, Inghirami G, Di Napoli A. Does Breast Implant-Associated ALCL Begin as a Lymphoproliferative Disorder? Plast Reconstr Surg. 2020;145(1):30e-38e.

Lui GY, Shaw R, Schaub FX, Stork IN, Gurley KE, Bridgwater C, et al. BET, SRC, and BCL2 family inhibitors are synergistic drug combinations with PARP inhibitors in ovarian cancer. EBioMedicine. 2020;60:102988.